Comparative in vitro activity of gemifloxacin
Authors:
Open Access
- 1 April 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 45 (90003) , 1
Abstract
Gemifloxacin is a new quinolone and, like moxifloxacin, trovafloxacin, grepafloxacin and clinafloxacin, is more potent in vitro than ciprofloxacin or ofloxacin against Gram-positive aerobes. Gemifloxacin was the most potent of the quinolones tested against streptococci and most ciprofloxacin-resistant pneumococci were susceptible to gemifloxacin. Gemifloxacin, like moxifloxacin, trovafloxacin, grepafloxacin and clinafloxacin, was more potent than ciprofloxacin or ofloxacin against all staphylococci and many ciprofloxacin-resistant isolates were susceptible to these quinolones. Against Gram-negative aerobes gemifloxacin was as potent as or slightly less potent than ciprofloxacin, and isolates resistant to ciprofloxacin were also resistant to gemifloxacin and to moxifloxacin, trovafloxacin and grepafloxacin. Gemifloxacin was also the most potent quinolone against Gram-positive anaerobes and fusobacteria but trovafloxacin was the most potent agent tested against other Gram-negative anaerobes.Keywords
This publication has 6 references indexed in Scilit:
- In Vitro Activity of Gemifloxacin (SB 265805) against AnaerobesAntimicrobial Agents and Chemotherapy, 1999
- A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new ‘respiratory quinolones’Journal of Antimicrobial Chemotherapy, 1999
- International multicenter investigation of LB203W. a new fluoronaphthyridoneClinical Microbiology and Infection, 1998
- In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolatesJournal of Antimicrobial Chemotherapy, 1997
- In vitro activity of BAY 12-8039, a new fluoroquinoloneAntimicrobial Agents and Chemotherapy, 1997
- In vitro activity of OPC-17116Antimicrobial Agents and Chemotherapy, 1992